Analysis of factors for association with mutation detection
Factor . | No. subjects . | Mutation, no. . | Univariate P . | Multivariate P (n = 60) . | Estimated odds ratio . | 95% Wald confidence interval . |
|---|---|---|---|---|---|---|
| Sex | ||||||
| Male | 38 | 10 | 420 | NA | NA | NA |
| Female | 28 | 5 | ||||
| Age* | ||||||
| 60 y or younger | 39 | 6 | 093 | NS | NA | NA |
| Older than 60 y | 27 | 9 | ||||
| Disease duration | ||||||
| 12 mo or fewer | 17 | 2 | 211 | NA | NA | NA |
| Longer than 12 mo | 48 | 13 | ||||
| Prior therapy | ||||||
| None, HU, IFN | 35 | 9 | 593 | NA | NA | NA |
| Others | 31 | 6 | ||||
| Prior treatment with 6-thioguanine*† | ||||||
| Yes | 6 | 4 | 018 | 006 | 43.295 | 2.916-642.928 |
| No | 60 | 11 | ||||
| Phase* | ||||||
| Chronic | 20 | 0 | 003 | NS | NA | NA |
| Accelerated + blastic | 46 | 15 | ||||
| Clonal evolution* | ||||||
| Yes | 26 | 11 | 003 | 006 | 14.163 | 2.083-96.316 |
| No | 36 | 3 | ||||
| Splenomegaly | ||||||
| Yes | 46 | 14 | 127 | NA | NA | NA |
| No | 13 | 1 | ||||
| Hemoglobin level | ||||||
| More than 100 g/L | 26 | 7 | 548 | NA | NA | NA |
| Less than 100 g/L | 39 | 8 | ||||
| White blood cell count | ||||||
| More than 10 × 109/L | 19 | 2 | 148 | NA | NA | NA |
| Fewer than 10 × 109/L | 47 | 13 | ||||
| Platelets ()*‡ | ||||||
| Fewer than 100 × 109/L | 17 | 8 | 013 | 007 | 19.682 | 2.160-179.361 |
| At least 100 × 109/L but fewer than 450 × 109/L | 30 | 4 | ||||
| At least 450 × 109/L | 17 | 3 | ||||
| Blasts in PB | ||||||
| 5% or less | 43 | 11 | 563 | NA | NA | NA |
| More than 5% | 21 | 4 | ||||
| Basophils in PB | ||||||
| 7% or less | 43 | 12 | 122 | NA | NA | NA |
| More than 7% | 20 | 2 | ||||
| Blasts in BM | ||||||
| 5% or less | 30 | 6 | 401 | NA | NA | NA |
| More than 5% | 27 | 8 |
Factor . | No. subjects . | Mutation, no. . | Univariate P . | Multivariate P (n = 60) . | Estimated odds ratio . | 95% Wald confidence interval . |
|---|---|---|---|---|---|---|
| Sex | ||||||
| Male | 38 | 10 | 420 | NA | NA | NA |
| Female | 28 | 5 | ||||
| Age* | ||||||
| 60 y or younger | 39 | 6 | 093 | NS | NA | NA |
| Older than 60 y | 27 | 9 | ||||
| Disease duration | ||||||
| 12 mo or fewer | 17 | 2 | 211 | NA | NA | NA |
| Longer than 12 mo | 48 | 13 | ||||
| Prior therapy | ||||||
| None, HU, IFN | 35 | 9 | 593 | NA | NA | NA |
| Others | 31 | 6 | ||||
| Prior treatment with 6-thioguanine*† | ||||||
| Yes | 6 | 4 | 018 | 006 | 43.295 | 2.916-642.928 |
| No | 60 | 11 | ||||
| Phase* | ||||||
| Chronic | 20 | 0 | 003 | NS | NA | NA |
| Accelerated + blastic | 46 | 15 | ||||
| Clonal evolution* | ||||||
| Yes | 26 | 11 | 003 | 006 | 14.163 | 2.083-96.316 |
| No | 36 | 3 | ||||
| Splenomegaly | ||||||
| Yes | 46 | 14 | 127 | NA | NA | NA |
| No | 13 | 1 | ||||
| Hemoglobin level | ||||||
| More than 100 g/L | 26 | 7 | 548 | NA | NA | NA |
| Less than 100 g/L | 39 | 8 | ||||
| White blood cell count | ||||||
| More than 10 × 109/L | 19 | 2 | 148 | NA | NA | NA |
| Fewer than 10 × 109/L | 47 | 13 | ||||
| Platelets ()*‡ | ||||||
| Fewer than 100 × 109/L | 17 | 8 | 013 | 007 | 19.682 | 2.160-179.361 |
| At least 100 × 109/L but fewer than 450 × 109/L | 30 | 4 | ||||
| At least 450 × 109/L | 17 | 3 | ||||
| Blasts in PB | ||||||
| 5% or less | 43 | 11 | 563 | NA | NA | NA |
| More than 5% | 21 | 4 | ||||
| Basophils in PB | ||||||
| 7% or less | 43 | 12 | 122 | NA | NA | NA |
| More than 7% | 20 | 2 | ||||
| Blasts in BM | ||||||
| 5% or less | 30 | 6 | 401 | NA | NA | NA |
| More than 5% | 27 | 8 |
NS indicates not significant; PB, peripheral blood; BM, bone marrow; and NA, not applicable.
Factors with P < .1 in univariate analysis were included in the multivariate model.
Other antileukemic therapies were also analyzed individually for their effect on mutation frequency, but no significant associations were detected.
Significant only for comparison between platelets fewer than 100 and platelets of at least 100 but fewer than 450 (normal range).